Microbiome of the Lung and Respiratory Tract in HIV-Infected Individuals and HIV-Uninfected Controls (U01)

archived

Purpose.The National Heart, Lung, and Blood Institute (NHLBI) solicits grant applications under this Funding Opportunity Announcement (FOA) to characterize the microbiome of the lung (the airways and airspaces below the glottis and the lung parenchyma) alone or in combination with the nasal and/or oropharyngeal cavities in HIV-infected individuals and matched HIV-uninfected controls, including normal healthy controls, using molecular techniques to identify bacteria and if possible other organisms, e.g., viruses, cell-wall deficient organisms, protozoa, and fungi. Investigators should use high-throughput technology platforms to create a data set of sufficient quality and depth to allow analysis of how changes of microbiota relate to HIV lung disease progression/complications.These data will be used to examine the impact of changes in the respiratory microbiome on the pathogenesis and progression of HIV disease, on HIV-related respiratory complications, and the effects of anti-HIV therapies. The National Heart, Lung, and Blood Institute (NHLBI) invites applications for four Clinical/Sequencing research sites and one supporting Data Coordinating Center (DCC).Each application for a clinical/sequencing research site should propose approaches to characterize the lung microbiome and applicants are encouraged to include at least one hypothesis-driven mechanistic aim.Applicants must agree to collaborate with the other Clinical/Sequencing sites, the DCC, and projects funded under the Roadmap HMP program on overlapping areas of interest.Inclusion of the nasal and or pharyngeal cavities is optional.The Lung HIV Microbiome Program is designed to promote cooperation and coordination, facilitate scientific exchange, and leverage resources.

High